XERS
Is Xeris Biopharma Holdings (XERS) a good Buffett stock?
Xeris Biopharma Holdings (XERS) is analysed against the documented Warren Buffett framework on this page. The Buffett-Fit score rates the stock from 0 to 100 across five pillars (moat, earnings durability, management quality, financial health, valuation), each on a 0-100 sub-scale. The full reasoning behind every pillar is below. Educational only, not investment advice.
Five pillars at a glance. Xeris Biopharma Holdings's Buffett-Fit score weighs ROIC sustainability (currently 0.1%), gross-margin durability (0.8%), net-debt-to-EBITDA (-1.66x), free-cash-flow conversion (50.42x net income), and the owner-earnings yield (2.5%). Each pillar is scored 0-100 against sector-relative benchmarks.
Where XERS passes the test. A Buffett-style holding needs durable returns, conservative debt, owner-friendly management, and a price below intrinsic value. The full pillar breakdown on /buffett/xers/ shows where Xeris Biopharma Holdings clears each bar, and where it doesn't.
What the score does NOT say. A high Buffett-Fit score is a pattern-match against documented criteria, not a forecast. A stock scoring 90 today can underperform if its underlying business deteriorates faster than the score updates. A stock scoring 30 can outperform if the business recovers. The score weighs current fundamentals against a documented framework: that's all it claims to do.
How invest-like measures this
The Buffett-Fit framework on invest-like scores any public stock from 0 to 100 across five weighted pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety).
Each pillar is scored on the same 0-100 sub-scale using the rubric Warren Buffett has documented across 50+ years of Berkshire Hathaway shareholder letters. The overall score is the weighted average. Educational only, pattern-match against documented public criteria, not personalised investment advice.
Il s'agit d'une analyse éducative fondée sur des méthodes d'investissement. Ce n'est ni un conseil ni une recommandation, et elle ne connaît pas ta situation. Fais tes propres recherches avant de décider.
